Overview of Nebistar-SA

Property	Description
Active Ingredients	Nebivolol, Levamlodipine
Form	Oral Tablet
Pharmacological Class	Antihypertensive Agents (Beta-blocker + CCB)
General Purpose	Control of high blood pressure (Hypertension)
Origin	Synthetic Compounds

Nebistar-SA is a synthetic pharmaceutical preparation supplied as an oral tablet, classified broadly as an Antihypertensive Agent. This medication is a Fixed-Dose Combination (FDC), which means it integrates two distinct active ingredients into a single preparation to provide a comprehensive and synergistic action against elevated arterial pressure. This combination is typically prescribed for adults whose blood pressure is inadequately controlled by either component taken alone.

What Type of Medicine is Nebistar-SA?

Nebistar-SA is a combination therapy belonging to two major, clinically recognized classes of cardiovascular medication: a Beta-blocker and a Calcium Channel Blocker (CCB). The use of an FDC is an established strategy for managing hypertension, as clinical data confirm that combining agents often provides superior blood pressure control compared to using monotherapy alone. This dual approach efficiently addresses two distinct physiological mechanisms that contribute to high blood pressure.

The Active Components: Levamlodipine and Nebivolol

The medication's composition features the two active ingredients: Levamlodipine and Nebivolol. Levamlodipine, the pharmacologically active enantiomer (S-isomer) of the CCB Amlodipine, primarily targets the reduction of vascular resistance. Nebivolol is classified as a third-generation Beta-blocker and is differentiated from older beta-blockers by its ability to promote vasodilation through Nitric Oxide stimulation. This characteristic of Nebivolol provides a distinct benefit by not only helping the heart but also aiding in peripheral vessel widening.

General Purpose and Dual Mechanism

The primary general purpose of Nebistar-SA is to achieve effective and sustainable control of hypertension. The medication works through a dual physiological action: Levamlodipine facilitates vessel relaxation, reducing overall peripheral vascular resistance, while Nebivolol acts to reduce the heart's effort by slowing the heart rate and lessening the force of its contraction. This balanced, two-pronged mechanism addresses both vascular tone and cardiac output, which are the fundamental determinants of blood pressure.

What side effects are possible with Nebistar-SA?

Possible Side Effects and Safety Information

The safety profile for this fixed-dose combination (Nebivolol/Levamlodipine) is defined by the adverse reactions and regulatory warnings documented for its component drugs, as classified by government health authorities.

Adverse Reaction Classifications

Side effects are primarily categorized by frequency and the body system affected, according to official labeling:

Classification	Examples of Documented Reactions
Common (generally ge 1%)	Headache, dizziness, fatigue (asthenia), peripheral oedema (ankle swelling), slow heart rate (bradycardia), palpitations, nausea.
Uncommon (generally <1%)	Insomnia, rash, dyspepsia, dry mouth, blurred vision, hypotension.

These reactions primarily affect the Nervous System (headache, dizziness), Vascular system (peripheral oedema, hypotension), Cardiac system (bradycardia, palpitations), and Gastrointestinal system (nausea, constipation).

Serious Adverse Reactions and Safety Constraints

The official labeling includes specific warnings about clinically significant risks and population-based constraints:

Abrupt Cessation Risk: Stopping the medication suddenly, particularly in patients with existing coronary artery disease, is documented as a risk for severe exacerbation of angina, myocardial infarction, or ventricular arrhythmias.
Contraindications: The medicine is contraindicated in conditions such as severe bradycardia (very slow heart rate), second or third degree heart block, cardiogenic shock, decompensated heart failure, and severe hepatic impairment.
Masked Symptoms: The Beta-blocker component may mask physical signs of hypoglycemia (low blood sugar) in diabetic patients and symptoms of hyperthyroidism (overactive thyroid).

Safety Profile Summary

This regulatory structure emphasizes that while minor effects like headache and oedema are common, the primary safety focus involves absolute restrictions on use in severe cardiovascular or liver impairment, and the critical risk associated with abrupt treatment discontinuation.

Overdose and Emergency Response

The official regulatory profile for an overdose of Nebistar-SA (Nebivolol/Levamlodipine) describes acute clinical consequences resulting from the combined effect of a beta-blocker and a calcium channel blocker. The presentation of overdose includes severe cardiovascular manifestations such as marked and prolonged Systemic Hypotension, Bradycardia, and excessive Peripheral Vasodilatation. Patients may also experience dizziness, Syncope (fainting), or vomiting.

Life-threatening outcomes officially documented in regulatory labels include Shock (including cardiogenic shock), high-degree Heart Block, and Cardiac Failure. Respiratory complications, specifically Bronchospasm and the possibility of Non-cardiogenic Pulmonary Oedema, are also noted, along with metabolic issues like Hypoglycemia.

Immediate Medical Attention must be sought if an overdose is suspected or confirmed. Contacting emergency services is required. Management is symptomatic and supportive, as no specific antidote is officially documented. Supportive procedures described in regulatory guidance include Gastric Lavage, administration of Activated Charcoal, and the use of targeted drug therapies such as IV Calcium, Atropine, and Glucagon to address specific effects. Extended Clinical Monitoring is mandatory due to the prolonged half-life of one active component and the potential for delayed serious complications.

Therapeutic Uses of Nebistar-SA

What Nebistar-SA Treats: Main Uses and Benefits

Nebistar-SA is a combination medication applied in addressing conditions characterized by periods of heightened symptoms, such as hypertension (high blood pressure). Its use aligns with official guidance and is relevant when supportive symptom management is appropriate. The combination of active components contributes to managing symptoms related to systemic imbalance, which further contributes to easing the overall symptom load. This makes the medication useful in managing symptoms related to heightened physiological activity and those symptoms that interfere with daily functioning.

This medication is indicated for the treatment of hypertension. By helping to ease this systemic burden, Nebistar-SA helps maintain a sense of stability when symptoms are more noticeable. The supportive relief may help patients cope more steadily with symptom fluctuations, particularly those linked to organ-specific functional stress. It is commonly used across conditions presenting with acute episodes, such as hypertension, or high blood pressure, and it may be part of symptomatic management in clinical scenarios involving chronic physiological imbalance.

“This medication is commonly used to help with conditions presenting with systemic or localized discomfort related to high blood pressure.”

Quick Fact: Relief for symptoms related to physiological strain.

Eligibility and Restrictions for Use

The eligibility for Nebistar-SA (Nebivolol/S-Amlodipine) is strictly determined by official regulatory documents, which list absolute exclusions and populations requiring special caution. The medicine is intended for use in adults who do not have specific contraindications.

Contraindicated Populations (Must Not Use)

Use is prohibited for patients with:

Known hypersensitivity to nebivolol, S-amlodipine, or any other dihydropyridine derivatives.
Severe hepatic impairment (severe liver disease).
Acute heart failure, cardiogenic shock, or decompensated heart failure.
Severe bradycardia (very slow heart rate) or heart block greater than the first degree (without a pacemaker).
Severe hypotension, sick sinus syndrome (without a pacemaker), or bronchial asthma.

Use Limitations and Restrictions

Official labeling identifies populations that require caution or for whom the medicine is not recommended:

Population Category	Regulatory Status	Eligibility Basis
Pediatric Patients (Under 18)	Not Recommended	Safety and efficacy not established (insufficient data).
Pregnancy	Not Recommended	Use is generally discouraged unless deemed essential by a physician.
Lactation (Breastfeeding)	Not Recommended	Components may pass into breast milk.
Severe Renal Impairment	Caution Required	Requires close monitoring and potential dose adjustment.
Older Adults (Over 75)	Caution Required	Limited clinical experience; requires close monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Nebistar-SA reflects the combined risk posed by its two components, Nebivolol and Levamlodipine, as documented in official regulatory labeling.

Contraindicated and High-Risk Combinations

Interaction Type	Interacting Substances	Official Constraint
Pharmacodynamic	Intravenous Verapamil (or other Non-Dihydropyridine CCBs)	Contraindicated due to risk of profound hypotension and AV block.
Pharmacokinetic	Strong CYP3A Inhibitors (e.g., Fexinidazole, Tucatinib)	Restricted/Avoided, as they substantially increase Levamlodipine exposure.

Documented Pharmacokinetic and Additive Effects

Nebivolol is metabolized via the CYP2D6 enzyme. Co-administration with CYP2D6 inhibitors (e.g., Paroxetine, Fluoxetine) increases the plasma concentration of Nebivolol, which may raise the risk of excessive bradycardia. Levamlodipine is metabolized via CYP3A4; co-administration with other inhibitors requires close monitoring due to increased systemic exposure.

Several medications can cause additive effects, including other antihypertensive agents, Class I Antiarrhythmics, and Digitalis Glycosides, which may potentiate effects on heart rate or blood pressure. Additionally, Volatile Halogenated Anesthetics increase the risk of hypotension during concurrent use.

Other Interacting Substances and Timing Rules

Antacids: Administration of non-systemic antacids containing Aluminum or Magnesium may reduce the absorption of Nebivolol. The official documentation advises separating the dose of these antacids by at least two hours.
Food/Substances: Grapefruit juice may increase the systemic exposure of Levamlodipine and is generally advised to be avoided. Alcohol (ethanol) may also contribute to additive hypotensive effects.

Population-Specific Interaction Notes

In diabetic patients using oral hypoglycemics or insulin, Nebivolol may mask the physical symptoms of hypoglycemia, specifically tachycardia. Furthermore, in patients with severe hepatic impairment, the clearance of Nebivolol is decreased, leading to an elevated potential for adverse effects from the interaction.

Mechanism of Action

Adrenergic Receptor Modulation

This domain involves the action of Nebivolol as a highly selective antagonist of beta1-adrenergic receptors, primarily located in the myocardium. This action suppresses the signaling sequences initiated by sympathetic nervous system mediators (catecholamines), which typically increase heart rate and force of contraction. The receptor antagonism results in decreased heart rate and force of contraction (negative chronotropy and inotropy), which reduces the overall cardiac output.

Endothelial and Vascular Tone Regulation

This domain involves the combined effect of S-Amlodipine and Nebivolol on the vasculature. S-Amlodipine acts by inhibiting the influx of calcium ions through L-type calcium channels in the vascular smooth muscle cells. This modifies an early molecular step crucial for muscle contraction. Nebivolol additionally influences vascular tone via nitric oxide production through beta3-adrenergic receptor agonism in the endothelium, promoting relaxation of the peripheral blood vessels. The combined actions inhibit calcium-dependent contraction in vascular smooth muscle and increase local nitric oxide signaling in the endothelium, resulting in decreased systemic vascular resistance (SVR).

Dosage and Administration Information

Nebistar-SA is a fixed-dose combination (FDC) of Nebivolol and Levamlodipine that is administered orally as a single tablet once per day. This medicine is designated exclusively for substitution therapy and is not suitable for initiating treatment. This means the FDC is intended only for adult patients whose blood pressure is already adequately controlled by taking the individual components, Nebivolol and Levamlodipine, separately at the same established dose level.

The administration pattern requires taking the tablet once daily, preferably at the same time each day, to maintain consistent drug levels in the bloodstream. The medicine can be taken with or without meals. If a tablet is scored, the break-line is only present to facilitate swallowing and is not intended for dividing the dose for therapeutic adjustment. Any required change to the maintenance dose must be performed by switching back to the individual component tablets for titration.

Maximum blood pressure-lowering effects are generally achieved after two to four weeks of consistent administration, and treatment is typically a long-term regimen. For specific populations, the FDC is not recommended for use in individuals under 18 years of age. Use in older adults (above 75 years) requires close monitoring due to limited clinical experience. If a dose is missed, the standard procedure is skipping the forgotten dose entirely and continuing with the next scheduled dose at the usual time; compensation for the missed dose is not permitted.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nebistar-SA

Evidence from Studies for High Blood Pressure (Hypertension)

Research examining the use of Nebistar-SA (a combination of Nebivolol and S-Amlodipine) was studied for how it was associated with blood pressure measurements in adults diagnosed with essential hypertension. Randomized controlled trials (RCTs) were conducted in these research settings, where the research designs included comparisons against taking the individual components alone, or against a placebo (an inactive substance). Outcomes related to monitoring physiological strain or stress were observed, mainly measuring the change in blood pressure from the start of the study.

Trial Design and Short-Term Findings

The key studies were often short-term RCTs, with follow-up durations usually lasting a few months. Research explored how the drug combination related to the primary outcomes, which were the systolic and diastolic blood pressure readings. The data describe patterns related to measured changes in both of these readings across the study populations during the defined time intervals. The findings describe patterns observed in the studies in terms of how blood pressure changed under the specific conditions of the trial.

Long-Term Studies and Durability of Response

Currently, data from studies observing short-term changes are more common than long-term data. Based on the research available, there is limited information for long-term outcomes for the specific fixed-dose combination of Nebistar-SA. While the individual components have been observed in studies over longer periods, evidence specifically describing the durability of the response—meaning, what patterns are observed in blood pressure over one year or more with the single combination pill—is still emerging. Research so far indicates that more extended follow-up is necessary to fully establish long-term patterns related to cardiovascular measurements.

Evidence in Specific Patient Populations

Studies explored the use of the combination in adults, including specific groups like older adults (geriatric patients). Research also examined the combination in patients with conditions like diabetes, where outcomes reflecting systemic or functional imbalance are often relevant. The results apply only to the populations studied, and data for certain groups remain insufficient. For instance, there is limited information from trials concerning children, pregnant or breastfeeding individuals, or patients with severe pre-existing kidney or liver impairment using the Nebistar-SA combination.

What is Still Uncertain About Nebistar-SA Research

A few important points are not yet fully established in the current evidence landscape. While short-term changes in blood pressure are described, long-term outcomes are not fully established, particularly regarding major clinical events such as cardiac events. Comparative evidence remains insufficient for a direct, head-to-head comparison of Nebistar-SA against many other fixed-dose blood pressure drug combinations. The subgroup findings are uncertain when trying to generalize the short-term patterns to all patients with co-occurring health conditions due to data limitations. Evidence highlights what is known—and what is still uncertain—and emphasizes that research is ongoing to provide further context.

Frequently Asked Questions (FAQ)

Common questions about Nebistar-SA (FAQ)

Q: What happens if I stop taking Nebistar-SA suddenly?

Official regulatory warnings state that stopping this medication suddenly, especially in patients with coronary artery disease, carries a serious risk. Abrupt withdrawal may lead to a severe worsening of chest pain (angina), heart attack (myocardial infarction), or serious abnormal heart rhythms. Official instructions advise that treatment should be tapered gradually over 1 to 2 weeks, as directed by a healthcare provider.

Q: What are the long-term effects of taking Nebistar-SA?

Clinical studies for the specific fixed-dose combination are mostly short-term. While the individual components have extensive data, the long-term durability of the combination and its effect on major clinical outcomes like stroke or heart attack are still being established. More research is needed to fully understand long-term patterns.

Q: Does Nebistar-SA interact with common pain relievers like ibuprofen?

Regulatory information warns that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include common pain relievers like ibuprofen, may reduce the blood pressure-lowering effect of Nebistar-SA. If using NSAIDs consistently, a healthcare provider should monitor the combined effects.

Q: Is Nebistar-SA generally safe for people with liver issues?

According to official documentation, this medicine is contraindicated (must not be used) in patients with severe hepatic impairment (severe liver disease). Official labeling requires caution and close monitoring for individuals with less severe liver problems.

Q: How long does it take for the full effect of Nebistar-SA to be noticed?

The maximum blood pressure-lowering effects from Nebistar-SA are typically achieved after taking the medication consistently for two to four weeks. Treatment is usually a long-term regimen to maintain continuous blood pressure control.

Q: Why do some people say Nebistar-SA is different from older beta-blockers?

Nebivolol, one component of this medicine, is classified as a third-generation beta-blocker. It is differentiated from older types because, in addition to slowing the heart rate, it also promotes vasodilation (widening of blood vessels). This widening effect is achieved through its interaction with the body’s nitric oxide pathway.

Q: Are there any reports of hair loss linked to Nebistar-SA?

Hair loss (alopecia) is not generally listed among the Common or Uncommon side effects documented in the official safety profile for this fixed-dose combination. Side effects are classified based on how often they occurred in clinical trials.

Q: Can taking Nebistar-SA affect the results of other medical tests?

The beta-blocker component can mask the physical signs of certain conditions. Specifically, it can hide the signs of hypoglycemia (very low blood sugar) in diabetic patients or mask symptoms of hyperthyroidism (overactive thyroid). This masking effect is noted in the warnings and precautions section of the drug information.

Q: Is Nebistar-SA used for anxiety or just blood pressure?

Nebistar-SA is officially approved and indicated for the management of essential hypertension (high blood pressure) in adults. Anxiety is not an approved medical indication for this fixed-dose combination medicine.

Q: Does Nebistar-SA cause weight gain or weight loss?

Official regulatory documentation does not typically list significant changes in body weight (either gain or loss) among the most Common or Uncommon side effects reported in clinical trials for this specific combination.

Q: Can Nebistar-SA affect my sleep patterns?

Official regulatory reports list insomnia (difficulty sleeping) as an Uncommon side effect associated with the use of this medication.

Q: Does Nebistar-SA affect cholesterol levels?

Regulatory data generally do not indicate that this medicine causes significant changes in cholesterol or lipid levels as a common adverse reaction. Nebivolol data specifically suggests little to no effect on glucose or lipid metabolism in hypertensive patients.

Q: Is Nebistar-SA suitable for people with asthma or breathing problems?

Nebistar-SA is officially contraindicated (must not be used) in patients with bronchial asthma or acute heart failure. Eligibility for patients with existing breathing problems is determined by a healthcare provider.

Q: Do I need to change my diet while taking Nebistar-SA?

While taking this medication, official guidelines recommend avoiding or limiting consumption of grapefruit and grapefruit juice because it can increase the concentration of one of the active components (Levamlodipine) in the bloodstream. The official documentation does not mandate other specific changes to the general diet.

Q: Does Nebistar-SA cause erectile dysfunction or affect libido?

Official adverse reaction reports document that impotence (erectile dysfunction) and a decrease in libido are considered Uncommon side effects associated with this medication.

Q: Is Nebistar-SA known to cause dry mouth or dry eyes?

Dry mouth has been reported as an Uncommon side effect in clinical studies. However, dry eyes is generally not listed among the frequently reported adverse reactions for this medicine.

Q: How is Nebistar-SA excreted from the body?

The components are processed and eliminated in different ways. Nebivolol and its breakdown products are primarily removed via the urine and, to a lesser extent, the faeces. Levamlodipine is converted into inactive substances that are mainly eliminated through the urine.

Q: Is it normal to have cold hands and feet when taking Nebistar-SA?

Some patients may experience cold hands or feet. Paresthesia, which can include a feeling of tingling or coldness in the extremities, has been reported as a side effect of the medicine.

Q: Can Nebistar-SA affect blood sugar levels in non-diabetics?

The primary warning is that the medicine can mask the symptoms of low blood sugar in diabetic patients. Clinical research generally suggests that Nebivolol has little or no significant effect on glucose metabolism in hypertensive patients who do not have diabetes.

Q: Does Nebistar-SA make people sensitive to sunlight?

Photosensitivity reactions (increased sensitivity to the sun) are sometimes observed with the calcium channel blocker class. While not consistently listed as a Common or Uncommon side effect for this specific combination, sensitivity to sun exposure should be monitored by a patient and reported to a healthcare provider.

Q: What happens if I take more Nebistar-SA than prescribed?

Taking more than the prescribed amount of Nebistar-SA can lead to a serious overdose. Symptoms may include dangerously low blood pressure (severe hypotension), an excessively slow heart rate (excessive bradycardia), and potentially cardiogenic shock. Any suspected overdose requires immediate medical attention.

Q: Why is it important to check my pulse regularly on Nebistar-SA?

It is important to know that a potential and common side effect of the medicine is bradycardia (a slower-than-normal heart rate). Checking the pulse can help monitor for bradycardia, which is an important side effect.

Q: Does Nebistar-SA have a black box warning?

The medication does not typically carry a specific 'Black Box Warning' (the FDA's most serious safety alert) for the fixed combination itself. However, the beta-blocker component has a critical warning concerning the serious risks associated with suddenly stopping the medication, which is the type of information often highlighted in an FDA Boxed Warning.

Q: What are the signs of an allergic reaction to Nebistar-SA?

The medicine is contraindicated for those with a known hypersensitivity. Severe allergic reactions may include symptoms such as a rash, itching, swelling of the face, lips, or tongue, and difficulty breathing. If symptoms of a severe allergic reaction occur, immediate medical attention should be sought.

How should Nebistar-SA be stored and disposed of?

Storage and Disposal of Nebistar-SA

Nebistar-SA must be stored at Controlled Room Temperature, specifically 20 C to 25 C (68 F to 77 F). It is required to be stored in a tight and light-resistant container to protect the integrity of the tablets and must be protected from moisture. Storage in areas with excessive humidity, such as a bathroom, should be avoided.

Child Safety and Disposal

As a mandatory requirement, this medication must always be stored out of the reach and sight of children.

Unused or expired Nebistar-SA should be disposed of through a drug take-back program when available. If a program is not accessible, the product may be discarded in the household trash after being mixed with an undesirable substance, placed in a sealed container, and all personal information on the label is removed.

Nebistar-SA